Medtronic plc — Form 10-Q summary
Business context and reporting period
Medtronic is a global medical technology company with four reportable businesses: Cardiovascular, Medical Surgical, Neuroscience and Diabetes. This filing covers fiscal 2023 second quarter and first six months, ended October 28, 2022; comparisons are with the corresponding prior-year periods.
Key financial results
| Metric | Three months | Six months |
|---|---|---|
| Net sales | $7.585 billion, down 3% | $14.955 billion, down 6% |
| Operating profit | $1.404 billion, versus $1.563 billion | $2.528 billion, versus $2.422 billion |
| Net income attributable to Medtronic | $427 million, versus $1.311 billion | $1.356 billion, versus $2.074 billion |
| Diluted GAAP EPS | $0.32, versus $0.97 | $1.02, versus $1.53 |
| Operating cash flow | Not provided for the quarter | $2.005 billion, versus $3.061 billion |
| Free cash flow | Not provided for the quarter | $1.256 billion, versus $2.412 billion |
Quarterly operating margin was approximately 18.5%, compared with 19.9% a year earlier; six-month operating margin was approximately 16.9%, compared with 15.3%. The quarter’s effective tax rate rose to 68.7% from 11.8%, primarily due to a $764 million tax charge related to a U.S. Tax Court opinion. Excluding disclosed adjustments, non-GAAP diluted EPS was $1.30 for the quarter versus $1.32, and $2.42 for six months versus $2.68.
At October 28, cash and cash equivalents were $4.828 billion and current investments were $6.602 billion. Current assets were $25.398 billion and current liabilities $14.465 billion. Total debt was approximately $26.6 billion, versus $24.1 billion at fiscal year-end. The company reported $349 million of commercial paper outstanding and no borrowings under its $3.5 billion revolving credit facility.
Material changes and management commentary
- Sales declines were attributed principally to unfavorable foreign exchange and supply-chain challenges; the company also cited healthcare staffing constraints and pandemic-related effects on procedures. Non-U.S. developed-market sales fell 13% in the quarter, while U.S. sales rose 2%.
- Medical Surgical sales fell 10% in the quarter, Cardiovascular fell 2%, Neuroscience rose 2%, and Diabetes fell 5%. Strength in U.S. Neuroscience and certain product lines partly offset broader declines.
- Six-month operating cash flow declined $1.056 billion. Management cited slower customer collections and sales timing, higher income-tax payments, and increased inventory spending. Inventory increased to $5.055 billion from $4.616 billion at fiscal year-end.
- Investing cash outflow included $1.867 billion for acquisitions, principally Intersect ENT and Affera. The company also issued approximately $3.4 billion of Euro-denominated notes and used a ¥297 billion term loan to fund early debt redemptions; the redemptions resulted in a $53 million loss.
- Management described liquidity as strong and said cash, current investments, credit facilities and commercial-paper programs were expected to meet foreseeable operating needs. No quantified sales or EPS guidance is provided in the filing text.
Outlook, risks and unusual items
- Risks highlighted include currency movements, inflation, higher interest rates, supply disruptions (including electronic components and semiconductors), healthcare staffing and procedure-volume uncertainty, competitive and pricing pressure, regulatory approvals, reimbursement changes, and geopolitical developments.
- The company recorded $81 million of six-month non-cash charges related primarily to impairment in connection with the planned sale of half of Renal Care Solutions to DaVita. The transaction was expected to close in calendar 2023, subject to approvals and conditions.
- Medtronic announced in October 2022 an intention to separate its combined Patient Monitoring and Respiratory Interventions businesses; completion was expected 12–18 months after announcement.
- The Tax Court opinion concerning Puerto Rico/U.S. income allocation remains subject to finalization and potential appeal. Gross unrecognized tax benefits were $2.6 billion at quarter-end, with $196 million of accrued interest and penalties.
- Accrued litigation was approximately $0.3 billion. The filing discusses pelvic mesh, hernia mesh, environmental and other matters; the company notes outcomes and ultimate costs may differ materially from current estimates.
- Management said COVID-19 had not materially affected the reported consolidated financial statements for the quarter and six months, but future effects remain uncertain. It also noted possible future goodwill or intangible-asset impairments if conditions or expected performance deteriorate.
Important facts for investors to verify
- Whether sales and cash conversion improve as foreign-exchange headwinds, supply constraints, procedure volumes and customer collections evolve.
- The eventual tax and cash impact of the Tax Court matter, including any appeal and how findings may apply to later tax years.
- Progress, approvals, valuation and closing conditions for the DaVita transaction and the planned Patient Monitoring/Respiratory Interventions separation.
- Debt maturity and refinancing needs, including the stated plan to use Euro-note proceeds for upcoming note maturities, and the effect of higher interest rates.
- Developments in product liability, environmental and regulatory matters, and any resulting changes to accruals or business operations.